Skip to main content

Drug Interactions between fenfluramine and Relistor

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

fenfluramine methylnaltrexone

Applies to: fenfluramine and Relistor (methylnaltrexone)

MONITOR: Coadministration with fenfluramine may increase the plasma concentrations of drugs that are substrates of the multidrug and toxin extrusion 1 (MATE-1) efflux transporter. Fenfluramine is an inhibitor of the MATE-1 efflux transporter in vitro. However, clinical data are not available.

MANAGEMENT: Until more information is available, caution is advised when fenfluramine is coadministered with drugs that are substrates of the multidrug and toxin extrusion 1 (MATE-1) efflux transporter, particularly those with a narrow therapeutic range. If coadministration is required, clinical and laboratory monitoring for drug-related toxicities should be considered and the dosage adjusted as necessary in accordance with the product labeling of the coadministered drug.

References (3)
  1. (2023) "Product Information. Fintepla (fenfluramine)." UCB Pharma Ltd, SUPPL-13
  2. (2024) "Product Information. Fintepla (fenfluramine)." UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
  3. (2023) "Product Information. Fintepla (fenfluramine)." Prescript Pharmaceuticals, SUPPL-13

Drug and food interactions

Moderate

fenfluramine food

Applies to: fenfluramine

GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.

MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References (3)
  1. Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
  2. (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
  3. (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals
Moderate

methylnaltrexone food

Applies to: Relistor (methylnaltrexone)

ADJUST DOSING INTERVAL: Food may reduce the rate and extent of absorption of methylnaltrexone following oral administration. When a single 450 mg oral dose of methylnaltrexone was administered with a high-fat breakfast (approximately 800 to 1000 calories; 60% from fat, 25% from carbohydrate, and 15% from protein) in healthy study subjects, methylnaltrexone peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 60% and 43%, respectively, while time to reach Cmax delayed by 2 hours.

MANAGEMENT: Oral methylnaltrexone should be taken with water on an empty stomach at least 30 minutes before the first meal of the day.

References (1)
  1. (2008) "Product Information. Relistor (methylnaltrexone)." Wyeth Laboratories

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.